HIV/AIDS合并马尔尼菲篮状菌感染患者对伏立康唑交叉耐药的风险及交叉耐药机制
研究在体外诱导氟康唑耐药马尔尼菲篮状菌株,发现耐药株对伏立康唑MIC升高4至16倍,Cyp51B基因G441位点突变及外排泵AtrF、Mdr1、Pmfcz过表达与交叉耐药相关。
要点
- 氟康唑诱导的马尔尼菲篮状菌耐药株对伏立康唑MIC为0.25-1 mg/L,较敏感株0.06 mg/L升高4至16倍。
- 耐药株Cyp51B基因检出G441D和G441V两个突变热点。
- 绝大多数氟康唑耐药株中AtrF、Mdr1和Pmfcz基因显著过表达(P < 0.05)。
核心结论
- 马尔尼菲篮状菌在氟康唑存在下生长可在体外诱导对伏立康唑耐药,交叉耐药主要与Cyp51B基因G441位点突变及外排泵AtrF、Mdr1和Pmfcz过表达相关。
研究设计与样本
- 体外诱导氟康唑耐药马尔尼菲篮状菌株,对Cyp51B测序并用RT-qPCR测定所有菌株外排泵表达。
主要发现
- 氟康唑诱导耐药株对氟康唑敏感性大于128 mg/L,去除氟康唑压力后耐药性稳定遗传。
- 耐药株对伏立康唑MIC为0.25-1 mg/L,敏感株为0.06 mg/L,耐药株较敏感株升高4至16倍。
- Cyp51B检出G441D和G441V两个突变热点。
- 绝大多数氟康唑耐药株中AtrF、Mdr1和Pmfcz基因显著过表达(P < 0.05)。
关键数值与推荐
- 氟康唑诱导耐药株对氟康唑敏感性大于128 mg/L。
- 耐药株伏立康唑MIC为0.25-1 mg/L,敏感株为0.06 mg/L。
- Cyp51B突变热点为G441D和G441V。
- AtrF、Mdr1和Pmfcz在绝大多数耐药株中显著过表达(P < 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of fluconazole for long-term oral candidiasis treatment in HIV/AIDS patients can potentially affect the clearance rate and antifungal efficacy of voriconazole against Talaromyces marneffei infection. We isolated two T. marneffei strains that were both resistant to fluconazole and voriconazole. To investigate the mechanism underlying the induction of the cross-resistance in T. marneffei. METHODS: Fluconazole-resistant strains were induced in vitro. The target enzyme 14-α sterol demethylase Cyp51B was sequenced, and drug efflux pump expression was determined by RT-qPCR in all strains. RESULTS: The sensitivity of fluconazole-induced resistant strains to fluconazole was greater than 128 mg/L, and this resistance was stably inherited after fluconazole pressure was removed. MICs of voriconazole for resistant strains were 4∼16 times greater than FRR (0.25-1 versus 0.06 mg/L). Two mutation hotspots in Cyp51B were detected: G441D and G441V. The AtrF, Mdr1 and Pmfcz genes were significantly overexpressed in the vast majority of the fluconazole-resistant strains (P < 0.05). CONCLUSIONS: The growth of T. marneffei in the presence of fluconazole could induce voriconazole resistance in vitro. The main cause of this cross-resistance in T. marneffei appears to be related to a mutation in Cyp51B at G441 and overexpression of the efflux pumps AtrF, Mdr1 and Pmfcz.
引用
- Zheng YQ, Li QG, Latge JP, et al. Potential risk of cross-resistance to voriconazole in HIV/AIDS patients with Talaromyces marneffei infection and the mechanisms of the cross-resistance. J Antimicrob Chemother. 2025. PMID: 39871610. doi:10.1093/jac/dkaf022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。